《異動股》四環醫藥(00460.HK)急漲20%曾破頂再創近三年高 成交倍增
四環醫藥(00460.HK)繼上月22日升至2.32元創近三年高位遇阻掉頭回落股價始終守穩10天線,今天股價曾略破頂高見2.34元,現造2.28元,急漲20%,成交倍增至4.6億股,涉資9.9億元。
四環醫藥上周五公布,子公司軒竹生物自主研發用以治療非酒精性脂肪肝炎(NASH)的XZP-5610項目藥品,已於今年1月成功獲得國家藥品監督管理局批准開展臨床試驗。此外,上周四公布,集團注射液(克林澳)用於治療急性缺血性腦卒中的新適應症已於去年底獲得國家藥監局批准,其是目前內地開展藥品上市後臨床研究以來唯一獲批腦卒中治療領域的藥品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.